Abstracts tagged "osteoarthritis and subchondral bone"

Abstract Number: 436 • 2018 ACR/ARHP Annual Meeting
Structural Effects of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: A Post-Hoc Analysis of Cartilage Morphology over the 2-Year Treatment-Period of a 5-Year Randomized, Placebo-Controlled, Phase II Study
Ali Guermazi¹, Jeffrey Kraines², Aida Aydemir², Stephen Wax³, Michel Crema⁴, Marc C. Hochberg⁵ and Frank Roemer^1,6, ¹Radiology, Boston University School of Medicine, Boston, MA, ²EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵University of Maryland School of Medicine, Baltimore, MD, ⁶Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Sprifermin, a recombinant human fibroblast growth factor 18, is currently being investigated as a potential disease-modifying OA drug. Sprifermin treatment leads to a dose-dependent…
Abstract Number: 1130 • 2015 ACR/ARHP Annual Meeting
Global DNA Methylation Analysis of Osteoarthritic Subchondral Bone Reveals Significant Regional Variation and Similarity to Overlying Cartilage
Matlock A. Jeffries^1,2, Madison Andrews³, Mary Beth Humphrey¹, Judith A. James⁴ and Amr H. Sawalha⁵, ¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Association, Oklahoma City, OK, ³Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Univers, Oklahoma City, OK
Background/Purpose: Osteoarthritis (OA) is a leading cause of chronic disability affecting a majority of individuals over age 70. Outside of cartilage, little is known regarding…
Abstract Number: 1007 • 2014 ACR/ARHP Annual Meeting
Markedly Increased Mesenchymal Stem Cell Activity in MRI Bone Marrow Lesions Compared with Non-Involved Bone in Osteoarthritic Hips
T Mark Campbell¹, Frederique Ponchel², Alexandro Gomez³, Richard J. Hodgson², Dennis McGonagle⁴, Philip G. Conaghan⁵ and Elena Jones³, ¹Medicine, The Ottawa Hospital Rehabilitation Centre, Ottawa, ON, Canada, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Musculoskeletal Biomedical Research Unit, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, United Kingdom
Background/Purpose Multipotent mesenchymal stem cells (MSCs) are critical for bone and cartilage repair but the role of such cells in vivo in hip OA is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].